VX-407 for polycystic kidney, autosomal dominant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Sep 2025: Trial registered, NCT07161037
  2. 19 Nov 2025: Trial started, NCT07161037

The trials

NCT07161037: Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

State
Under way
Phase
Phase 2
People
26 taking part
Started
19 Nov 2025
Primary completion
22 Jul 2027
Arms
VX-407
Results
None posted
  1. 8 Sep 2025: Trial registered
  2. 19 Nov 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.